Kailera Therapeutics, Inc. Common Stock (KLRA) Stock
NYSE · KLRA
12.83
Fundamentals
Market cap
$1.66B
Price / Earnings ratio
-11.2x
Price / Sales ratio
N/A
Price / Book ratio
1.5x
Return on assets
N/A
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Kailera Therapeutics, Inc. Common Stock
Kailera Therapeutics is an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment.
SectorHealthcare
IndustryBiotechnology
Employees145
CEOMr. Ronald C. Renaud Jr., M.B.A.
IPO DateApr 17, 2026
HeadquartersWaltham, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Ronald C. Renaud Jr., M.B.A. | President, CEO & Director | 1969 |
| Mr. Paul Douglas Burgess J.D., M.S. | Chief Operating & Business Officer | 1974 |
| Ms. Jamie Beth Coleman | Chief Commercial Officer | 1978 |
| Mr. Douglas W. Pagan M.B.A. | Chief Financial Officer | 1972 |
| Maura Gavaghan | Vice President of Corporate Communications & Investor Relations | — |
| Mr. Scott M. Akamine J.D. | Chief Legal Officer & Secretary | 1985 |
| Ms. Paula A. Cloghessy SHRM-SCP, SPHR | Chief People Officer | 1972 |
| Dr. Scott M. Wasserman M.D. | Chief Medical Officer | 1970 |
| Ms. Kathleen Tregoning M.A. | Chief Corporate Affairs Officer | 1971 |
| Mr. Corey Manchester | Treasurer | — |
Fundamentals
Valuation
Market cap$1.66B
Price-to-sales ratioN/A
Price-to-book value1.50
Price-earnings ratio-11.20
Return on EquityN/A
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-949.00
Income Statement
Average volume874,301
EBITDA$-147.99M
1 year high (52w)$28.23
1 year low (52w)$12.47
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



